Associating sleep problems with advanced cancer diagnosis, and immune checkpoint treatment outcomes: a pilot study

Background: Sleep problems (SP) are common in cancer patients but have not been previously assessed in patients receiving immune checkpoint inhibitors (ICI).Methods: We collected questionnaire data on sleep apnea risk, insomnia and general sleep patterns. We used an adjusted multivariate Poisson regression to calculate prevalence ratios (PRs) and associated 95% confidence intervals (CIs) for associations between these SP and metastatic versus localized cancer stage (M1 vs M0), and adjusted logistic regression models to calculate ORs for associations between SP with the number of ICI infusions completed (6+ vs. Results: Among 32 patients who received ICI treatment, the prevalence of low, intermediate, and high-risk OSA risk was 36%, 42%, and 21%, respectively. Overall, 58% of participants reported clinically significant insomnia. We did not find a significant association between intermediate or high risk OSA (vs. low risk) and metastatic cancer status [PR=1.01 (95% CI: 0.28, 3.67)]. Patients in the cohort who reported taking >15 minutes to fall asleep were 3.6 times more likely to be diagnosed with metastatic cancer compared to those reporting shorter sleep latency [95% CI (1.74, 7.35)]. We did not find a significant association between SP and number of ICI infusions completed.Conclusion: Our data associating sleep apnea risk, insomnia and sleep patterns with more advanced cancer encourages further exploration in larger-scale observational studies and suggests interventional clinical trials focused on sleep quality improvement could result in better outcomes for these patients.